Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.72 USD
+0.17 (6.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.72 USD
+0.17 (6.46%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
by Zacks Equity Research
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
by Zacks Equity Research
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
Should You Buy Allogene Therapeutics (ALLO) Ahead of Earnings?
by Zacks Equity Research
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.
Perrigo (PRGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.
Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 278.19%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 278.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
by Zacks Equity Research
Dermata (DRMA) gains on positive FDA response for the further development of DMT310 for treating severe to moderate acne.
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
VYNE Gains on Preclinical Data for IPF Candidate
by Zacks Equity Research
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
by Zacks Equity Research
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.
Gamida Cell (GMDA) Surges on FDA Approval for Omisirge
by Zacks Equity Research
Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
by Zacks Equity Research
Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.
Alvotech (ALVO) Declines on CRL for Humira's Biosimilar Candidate
by Zacks Equity Research
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.